CAI Tian, KANG Bing-hao, CHENG Yue, HUANG Min, ZHAO Lin-xiang. Research progress of DNA-PK inhibitors in the cancer treatmentJ. Acta Pharmaceutica Sinica, 2023, 58(8): 2218-2225. DOI: 10.16438/j.0513-4870.2023-0486
Citation: CAI Tian, KANG Bing-hao, CHENG Yue, HUANG Min, ZHAO Lin-xiang. Research progress of DNA-PK inhibitors in the cancer treatmentJ. Acta Pharmaceutica Sinica, 2023, 58(8): 2218-2225. DOI: 10.16438/j.0513-4870.2023-0486

Research progress of DNA-PK inhibitors in the cancer treatment

  • The most toxic DNA damage is DNA double strand breaks (DSBs), which are mainly repaired by non-homologous end joining (NHEJ). DNA-dependent protein kinase (DNA-PK) belongs to phosphatidylinositol-3-kinase-related protein kinase family (PIKK) and plays a key role in NHEJ. DNA-PK is overexpressed in a variety of cancer cells and is related to the occurrence, development and drug resistance of malignant tumors. In this article, the representative DNA-PK inhibitors with anticancer effects are reviewed, in order to provide a reference to discovery novel DNA-PK inhibitors.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return